SRR12475152
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.560
- MYC_TARGETS_V1+0.520
- OXIDATIVE_PHOSPHORYLATION+0.470
- E2F_TARGETS+0.420
- DNA_REPAIR+0.320
- MTORC1_SIGNALING+0.310
- UNFOLDED_PROTEIN_RESPONSE+0.310
- FATTY_ACID_METABOLISM+0.250
- G2M_CHECKPOINT+0.240
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.190
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.480
- TGF_BETA_SIGNALING-0.470
- UV_RESPONSE_DN-0.390
- KRAS_SIGNALING_UP-0.380
- ANGIOGENESIS-0.340
- INFLAMMATORY_RESPONSE-0.340
- COAGULATION-0.300
- MYOGENESIS-0.300
- TNFA_SIGNALING_VIA_NFKB-0.300
- IL2_STAT5_SIGNALING-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 513fb61a-1339-45d2-8963-6337e3aff5df | — | — | 0.900 |
| 2 | SRR12475110 | — | — | 0.892 |
| 3 | 3d1f89ec-ac0b-40f8-ac89-ed0c2d4967b7 | — | — | 0.891 |
| 4 | ERR2208932 | — | — | 0.890 |
| 5 | TCGA-66-2763-01A-01R-0851-07 | — | cohortSQ1 | 0.883 |
| 6 | SRR11296797 | — | — | 0.875 |
| 7 | 7612ab8d-b99d-4b3b-a157-fe93e277ecf5 | — | — | 0.872 |
| 8 | 26596228-9935-4e5d-8e41-d10f51e0f364 | — | — | 0.871 |
| 9 | 504282dd-4fef-4f70-a709-6a545d00a263 | — | — | 0.870 |
| 10 | TCGA-33-AASJ-01A-11R-A405-07 | — | cohortSQ2 | 0.866 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.560 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.520 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.470 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.320 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.310 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.310 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.120 | Inavolisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.090 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.030 | Remibrutinib | — uncovered |